Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

ALNY
Alnylam Pharmaceuticals, Inc.
stock NASDAQ

At Close
Aug 20, 2026 3:59:57 PM EDT
229.30USD-5.484%(-13.31)1,685,972
212.80Bid   255.91Ask   43.11Spread
Pre-market
Aug 20, 2026 9:19:30 AM EDT
241.13USD-0.610%(-1.48)515
After-hours
Aug 20, 2026 4:00:30 PM EDT
228.76USD-0.238%(-0.54)187,141
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsTrends
ALNY Reddit Mentions
Subreddits
Limit Labels     

We have sentiment values and mention counts going back to 2017. The complete data set is available via the API.
Take me to the API
ALNY Specific Mentions
As of Aug 20, 2026 4:10:03 PM EDT (1 min. ago)
Includes all comments and posts. Mentions per user per ticker capped at one per hour.
4 days ago • u/Tallwhitedude123 • r/ValueInvesting • my_scanner_ranks_1921_us_stocks_and_papertrades • C
Doing my own research I personally came across ALNY myself. I like it but I like RARE better so I pulled the trigger on RARE instead. I also like APP. As far as the others they don’t fit my style.
I possibly might still buy shares of ALNY as it is certainly undervalued, in my opinion
sentiment 0.97
4 days ago • u/mferarg • r/ValueInvesting • my_scanner_ranks_1921_us_stocks_and_papertrades • Stock Analysis • B
I've built a scanner that scores about 1,921 US-listed companies. This week, 207 names were filtered out by checks against untrustworthy numbers. Here's my current top-10 undervalued list.
|\#|Ticker|Company|Price|Upside to fair value|Off 52-wk high|
|:-|:-|:-|:-|:-|:-|
|1|ALNY|Alnylam Pharmaceuticals|$228.65|\+106%|\-54%|
|2|RGLD|Royal Gold|$230.68|\+80%|\-25%|
|3|PLMR|Palomar Holdings|$128.21|\+94%|\-13%|
|4|MELI|MercadoLibre|$1,844.58|\+99%|\-28%|
|5|HL|Hecla Mining|$18.37|\+68%|\-46%|
|6|AUB|Atlantic Union Bankshares|$42.88|\+118%|\-2%|
|7|OWL|Blue Owl Capital|$12.22|\+92%|\-37%|
|8|APP|Applovin|$315.44|\+93%|\-58%|
|9|BRO|Brown & Brown|$70.54|\+62%|\-28%|
|10|NBIX|Neurocrine Biosciences|$152.72|\+78%|\-18%|
**What stands out in the top names**
**Alnylam Pharmaceuticals (healthcare)** is 54% off its 52-week high with revenue up 95% in the same stretch. The engine's fair value sits +106% above today's price.
**Royal Gold (basic materials)** has revenue up 94% year on year while the price sits 25% below its high. The engine's fair value sits +80% above today's price.
**Palomar Holdings (financial services)** is growing revenue at 61% and priced at 11.3x forward earnings. The engine's fair value sits +94% above today's price.
**MercadoLibre (consumer cyclical)** trades 28% below its high after growing revenue 55%. The engine's fair value sits +99% above today's price.
**Hecla Mining (basic materials)** grew revenue 51% over the last twelve months and still trades 46% below its 52-week high. The engine's fair value sits +68% above today's price.
Whether any of these discounts is deserved is exactly the research a table like this is supposed to start, not replace.
**The track record, and why you should discount it**
The scanner runs a public paper portfolio on its own signals. Closed so far: 25 positions, all at their profit target, averaging +34.4% in about 49 days.
Don't read that as a 100% win rate. The book is young, and a closed sample from a young book skews toward fast winners by construction. Positions that hit their target quickly resolve first while the slow ones and the losers are still sitting in the open book. So those 25 closes just show what the early winners look like. Judge the system when the losers have had time to lose.
Here's the open book in full. 134 positions, 110 above entry and 24 below, median unrealized +12.5%, worst -11.1%.
On disposition effect, exits are mechanical. Every position gets a profit target and a stop loss the day it opens and closes automatically at whichever comes first, so nobody's choosing to hold losers. So far the targets have come first and the stops sit where they were set. Paper money, every trade logged publicly the day it happens, wins and losses alike.
**How the list is built**
About 1,921 US-listed companies get scored on valuation, fundamental quality and risk. Fair value comes from two anchors, the analyst target consensus and what the company has historically traded at on its own earnings. Analyst targets lag, so the second anchor does a lot of the work. The table's ranked by revenue growth over the last twelve months. They all clear the same valuation checks as every other list I post, so this is growth that's already priced like it isn't.
Some names get dropped before the list is built because their numbers can't be trusted. That filtered out 207 this week, 116 because there's no fair value worth trusting for them and 66 because their implied upside clears 120%, which almost always means a broken estimate.
I don't repeat names from recent weeks, so this is the best of what I haven't shown yet rather than the absolute top of the screen.
This is a screen. It's where research starts, not where it ends.
sentiment 0.99
4 days ago • u/Tallwhitedude123 • r/ValueInvesting • my_scanner_ranks_1921_us_stocks_and_papertrades • C
Doing my own research I personally came across ALNY myself. I like it but I like RARE better so I pulled the trigger on RARE instead. I also like APP. As far as the others they don’t fit my style.
I possibly might still buy shares of ALNY as it is certainly undervalued, in my opinion
sentiment 0.97
4 days ago • u/mferarg • r/ValueInvesting • my_scanner_ranks_1921_us_stocks_and_papertrades • Stock Analysis • B
I've built a scanner that scores about 1,921 US-listed companies. This week, 207 names were filtered out by checks against untrustworthy numbers. Here's my current top-10 undervalued list.
|\#|Ticker|Company|Price|Upside to fair value|Off 52-wk high|
|:-|:-|:-|:-|:-|:-|
|1|ALNY|Alnylam Pharmaceuticals|$228.65|\+106%|\-54%|
|2|RGLD|Royal Gold|$230.68|\+80%|\-25%|
|3|PLMR|Palomar Holdings|$128.21|\+94%|\-13%|
|4|MELI|MercadoLibre|$1,844.58|\+99%|\-28%|
|5|HL|Hecla Mining|$18.37|\+68%|\-46%|
|6|AUB|Atlantic Union Bankshares|$42.88|\+118%|\-2%|
|7|OWL|Blue Owl Capital|$12.22|\+92%|\-37%|
|8|APP|Applovin|$315.44|\+93%|\-58%|
|9|BRO|Brown & Brown|$70.54|\+62%|\-28%|
|10|NBIX|Neurocrine Biosciences|$152.72|\+78%|\-18%|
**What stands out in the top names**
**Alnylam Pharmaceuticals (healthcare)** is 54% off its 52-week high with revenue up 95% in the same stretch. The engine's fair value sits +106% above today's price.
**Royal Gold (basic materials)** has revenue up 94% year on year while the price sits 25% below its high. The engine's fair value sits +80% above today's price.
**Palomar Holdings (financial services)** is growing revenue at 61% and priced at 11.3x forward earnings. The engine's fair value sits +94% above today's price.
**MercadoLibre (consumer cyclical)** trades 28% below its high after growing revenue 55%. The engine's fair value sits +99% above today's price.
**Hecla Mining (basic materials)** grew revenue 51% over the last twelve months and still trades 46% below its 52-week high. The engine's fair value sits +68% above today's price.
Whether any of these discounts is deserved is exactly the research a table like this is supposed to start, not replace.
**The track record, and why you should discount it**
The scanner runs a public paper portfolio on its own signals. Closed so far: 25 positions, all at their profit target, averaging +34.4% in about 49 days.
Don't read that as a 100% win rate. The book is young, and a closed sample from a young book skews toward fast winners by construction. Positions that hit their target quickly resolve first while the slow ones and the losers are still sitting in the open book. So those 25 closes just show what the early winners look like. Judge the system when the losers have had time to lose.
Here's the open book in full. 134 positions, 110 above entry and 24 below, median unrealized +12.5%, worst -11.1%.
On disposition effect, exits are mechanical. Every position gets a profit target and a stop loss the day it opens and closes automatically at whichever comes first, so nobody's choosing to hold losers. So far the targets have come first and the stops sit where they were set. Paper money, every trade logged publicly the day it happens, wins and losses alike.
**How the list is built**
About 1,921 US-listed companies get scored on valuation, fundamental quality and risk. Fair value comes from two anchors, the analyst target consensus and what the company has historically traded at on its own earnings. Analyst targets lag, so the second anchor does a lot of the work. The table's ranked by revenue growth over the last twelve months. They all clear the same valuation checks as every other list I post, so this is growth that's already priced like it isn't.
Some names get dropped before the list is built because their numbers can't be trusted. That filtered out 207 this week, 116 because there's no fair value worth trusting for them and 66 because their implied upside clears 120%, which almost always means a broken estimate.
I don't repeat names from recent weeks, so this is the best of what I haven't shown yet rather than the absolute top of the screen.
This is a screen. It's where research starts, not where it ends.
sentiment 0.99


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC